All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • Market intelligence reports
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 15, 2019
Home » Topics » Clinical

Clinical
%{topic} RSS Feed RSS

insightec-exablate-neuro-12-13.png

Insightec low-intensity focused ultrasound opens blood-brain barrier in Alzheimer’s patients

December 13, 2019
By Stacy Lawrence
No Comments
There is no FDA-approved medication for Alzheimer’s disease. But there is some hope that if the blood-brain barrier could be more easily penetrated by drug candidates they would prove more effective. That is the line of research being pursued by Israeli company Insightec Ltd. via its Exablate Neuro that provides low-intensity focused ultrasound treatment.
Read More

Transgene shows TG-4010 the guillotine after NSCLC trial miss

December 13, 2019
By Michael Fitzhugh
No Comments
Transgene SA is quitting development of one of its lead therapeutic vaccines after a combination of the candidate, TG-4010, with chemotherapy and Opdivo (nivolumab, Bristol-Myers Squibb Co.) missed its primary endpoint in a phase II trial evaluating the combination as a first-line treatment for certain advanced non-squamous non-small-cell lung cancers.
Read More

Cautious optimism for Biolinerx’s CXCR4 inhibitor in pancreatic cancer

December 13, 2019
By David Ho
No Comments
HONG KONG – Israel-based Biolinerx Ltd. has unveiled the latest data from its ongoing phase IIa COMBAT/KEYNOTE-202 study at the European Society of Medical Oncology Immuno-Oncology Congress 2019 which evaluates Biolinerx’s BL-8040, an inhibitor of the chemokine receptor CXCR4, in combination with pembrolizumab and chemotherapy in second-line pancreatic cancer patients.
Read More

Abdominal snowman melts for Iterum but proposition solid with sulopenem in UTI

December 11, 2019
By Randy Osborne
No Comments
Shares of Iterum Therapeutics plc (NASDAQ:ITRM) slid 36%, or $1.73, to close at $3.12 after the Dublin-based firm disclosed the much-anticipated but less-than-stellar results from the phase III trial called Sulopenem for Resistant Enterobacteriaceae, or SURE 3, testing oral and I.V. versions of the drug in complicated intra-abdominal infections (cIAI).
Read More
ASH 2019

In all Candor, Darzalex has positive data

December 10, 2019
By Lee Landenberger
No Comments
ORLANDO, Fla. – As the enormous American Society of Hematology annual meeting wound down Tuesday, the Janssen Pharmaceutical Cos. of Johnson & Johnson released phase III data showing that adding Darzalex (daratumumab) to carfilzomib (Kyprolis from Amgen Inc.) and dexamethasone (DKd), compared to carfilzomib and dexamethasone (Kd) alone, significantly improved progression-free survival in patients with relapsed/refractory multiple myeloma.  
Read More
ASH-sickle-cell-disease-12-10
ASH 2019

‘Multiple ways’ of fighting once-incurable sickle cell disease

December 10, 2019
By Anette Breindl
No Comments
ORLANDO, Fla. – At the 61st American Society of Hematology (ASH) annual meeting late-breaking abstracts session on Tuesday, researchers from Boston Children’s Hospital reported that three adult patients who had received an autologous transplant of gene-edited hematopoietic stem cells lacking BCL11A produced high levels of functional hemoglobin and had reduced disease symptoms for at least eight months after transplantation. 
Read More
ASH 2019

Sanofi's sutimlimab delivers benefit for CAD patients in phase III study

December 10, 2019
By Michael Fitzhugh
No Comments
ORLANDO, Fla. – New research on sutimlimab, an investigational complement pathway inhibitor under development by Sanofi SA's Bioverativ unit, showed substantial benefits for people with the rare autoimmune disorder cold agglutinin disease (CAD).
Read More
Red blood cells
ASH 2019

Forty Seven’s data eat up the market, with positive results in MDS and AML

December 9, 2019
By Lee Landenberger
No Comments
ORLANDO, Fla. – Data from two studies from Forty Seven Inc. announced at the American Society of Hematology (ASH) annual meeting moved the market in a major way Monday as the company stock (NASDAQ:FTSV) soared 111% to close at $30.43, up $15.99.
Read More
ASH 2019

Constellation shares fall after myelofibrosis update, despite progress

December 9, 2019
By Michael Fitzhugh
No Comments
ORLANDO, Fla. – Preliminary data from a phase II test of Constellation Pharmaceuticals Inc.'s CPI-0610 in patients with myelofibrosis (MF), previewed to market adulation in November, got a full airing Monday at the American Society of Hematology (ASH) annual meeting.
Read More
CTAD 2019

Small Alzheimer’s drug companies look to advance quickly into late-stage

December 9, 2019
By Brian Orelli
No Comments
SAN DIEGO – Smaller companies looking to move their Alzheimer’s disease drugs into late-stage testing as quickly as possible are eschewing cognitive endpoints that can take years to readout for biomarkers and functional assays of brain activity.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 18 19 Next

Popular Stories

  • Bioworld MedTech’s Oncology Extra

    BioWorld MedTech
    Keeping you up to date on recent developments in oncology.
  • Ear-disorders

    FDA gives thumbs up to Cochlear’s implantable bone conduction hearing system

    BioWorld MedTech
    The U.S. FDA has cleared Cochlear Ltd.’s newest cochlear implant, the Osia 2 system, an active implantable bone conduction hearing system. Unlike Cochlear’s...
  • Drugs-pills-global-map-

    Analysis by U.K. startup Medbelle highlights extent of drug pricing disparity

    BioWorld
    LONDON – It’s no secret that American citizens pay the most for drugs, but the extent of the disparity is laid bare in a new index of the prices of 13 medicines...
  • Frankyoung-11-27

    Buoyed by optimism and love of family, former FDA chief Frank Young leaned into storms

    BioWorld
    Commissioner of the FDA for five years starting in 1984, Frank Young relished his position “at the vortex of controversy” as he sought to deal with the AIDS...
  • Biopharma companies continue their strong momentum in November

    BioWorld
    After being in the doldrums for the majority of the year, public biopharmaceutical companies, it appears, have turned the corner and are now on a major upswing.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Archives
    • Contact us
    • Cookie policy
    • Copyright notice
    • Privacy policy
    • Share your news
    • Staff
    • Terms of use
Follow Us

Copyright ©2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing